BIOVENTIX PLC

AGM Information • Dec 3, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

BIOVENTIX PLC - Result of AGM

PR Newswire

London, December 3

                             Bioventix plc                        ("Bioventix" or the "Company")                                 Result of AGMBioventix plc (AIM: BVXP) announces that at its Annual General Meeting heldearlier today, all resolutions put to shareholders were duly passed.For further information please contact:Bioventix plc              Chief Executive Officer    Tel: 01252 728 001Peter HarrisonfinnCap Ltd                Corporate Finance          Tel: 020 7220 0500Geoff Nash/Simon Hicks     Corporate BrokingStephen NorcrossAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.